The nicotine pouch market in the U.S. is entering a new stage of development as more products receive regulatory authorization.
The U.S. Food and Drug Administration (FDA) authorized four new On! nicotine pouches on August 4, 2026, through the Premarket Tobacco Product Application (PMTA) pathway, bringing the total number of FDA-authorized nicotine pouch products in the United States to 30.
While only four on! nicotine pouch products received authorization in this update, the decision highlights a broader industry trend: nicotine pouches are becoming an increasingly important category within the alternative nicotine market. Major nicotine pouch brands such as ZYN and On! continue to expand their presence as competition in the category grows.
Table of Contents
FDA Authorizes Four New On! Nicotine Pouches
The FDA authorized four new nicotine pouches on August 4, 2016, including:
- 2mg on! nicotine pouches Rich Berry
- 2mg on! nicotine pouches Autumn Spice
- 2mg on! nicotine pouches Cappuccino
- 4mg on! nicotine pouches Cappuccino
These products are manufactured by Helix Innovations LLC, an Altria Group operating company. This latest authorization strengthens Helix’s FDA-authorized nicotine pouch portfolio beyond its previously authorized On! PLUS products.
Unlike traditional tobacco products, nicotine pouches are designed for discreet oral use without combustion or vapor production, which has helped them gain attention among adult nicotine consumers seeking smoke-free alternative nicotine products.
The FDA stated that these products are currently authorized for lawful sale in the United States. According to their scientific product review, the products contained low levels of most harmful and potentially harmful constituents compared with other traditional oral and smokeless tobacco products.
However, FDA authorization applies only to the specific products reviewed and does not mean nicotine pouches are risk-free or “FDA approved” as completely safe products.
On! vs ZYN: FDA-Authorized Nicotine Pouch Market Landscape
As of August 4, 2016, the FDA had authorized 30 nicotine pouch products in the United States, including:
- 10 On! and On! PLUS nicotine pouch products
- 20 ZYN nicotine pouch products
On! and On! PLUS nicotine pouches are made by Altria subsidiary Helix Innovations, while ZYN nicotine pouches are manufactured by Philip Morris International subsidiary Swedish Match USA.
Both brands benefit from their parent companies’ regulatory expertise and resources. As no other nicotine pouch brands have received FDA marketing authorization in the U.S., ZYN and On! currently hold a leading position in the FDA-authorized nicotine pouch market.
However, FDA authorization applies to individual products, not entire brands. Each nicotine pouch product must complete its own review process based on the scientific evidence submitted by manufacturers.
How FDA Authorization Is Shaping the U.S. Nicotine Pouch Market
For nicotine pouch manufacturers, FDA authorization has become one of the most important factors shaping the U.S. nicotine pouch market.
Through the Premarket Tobacco Product Application (PMTA) process, companies must submit scientific evidence covering product characteristics, manufacturing standards, and potential public health impacts for FDA review.
The rigorous review process creates a high entry barrier for nicotine pouch manufacturers. Companies with stronger regulatory experience, research capacities, and financial resources may have advantages in completing the authorization process.
The current FDA-authorized market, led by On! and ZYN products, highlights the increasing importance of regulatory approval in shaping market competition.
What FDA Authorization Means for Nicotine Pouch Users
For nicotine pouch users, FDA authorization mainly means more transparency, clearer product information, and a better understanding of which products have completed regulatory review.
When a nicotine pouch product receives FDA authorization, it means that the specific product has completed the PMTA review process and is legally authorized for sale in the United States.
For consumers, this provides a clearer way to compare different nicotine pouch flavors, brands, and strengths by identifying products that have gone through FDA review. As more nicotine pouch products receive authorization, increased competition may also encourage more product choices, flavor options, nicotine strengths, and continued innovation within the category.
However, FDA authorization does not mean nicotine pouches are risk-free. These products still contain nicotine, and authorization confirms that a product has completed regulatory review — not that it is completely safe.
For everyday users, the main impact is that more nicotine pouch products with clearly defined regulatory status are becoming available in the U.S. market.
Final Thoughts
The FDA’s authorization of four new On! nicotine pouches marks another important step in the continued development of the U.S. nicotine pouch market.
With 30 FDA-authorized nicotine pouch products now available, nicotine pouches are becoming an increasingly important segment of the broader alternative nicotine market. As regulatory authorization continues to shape competition, brands with FDA-authorized products may have advantages in building consumer trust and expanding their presence in the U.S. market.
Looking ahead, the nicotine pouch category is expected to continue evolving, with future competition focused on product innovation, user experience, flavor development, and regulatory compliance. As more products enter the FDA review process, regulatory authorization will continue to play an important role in shaping the future of the U.S. nicotine pouch market.
FAQs
Q1: How many nicotine pouches are FDA-authorized in 2026?
As of August 2026, the FDA has authorized 30 nicotine pouch products in the United States, including 10 made by Altria subsidiary Helix Innovations and 20 ZYN products made by Philip Morris International subsidiary Swedish Match USA.
Q2: What brand of nicotine pouches received FDA authorization in this update?
The four newly authorized nicotine pouch products are from the on! brand, manufactured by Helix Innovations LLC, an operating company of Altria Group. The authorized products include Rich Berry 2 mg, Autumn Spice 2 mg, Cappuccino 2 mg, and Cappuccino 4 mg nicotine pouches.
Q3: Are all nicotine pouches FDA-authorized?
No. FDA authorization only applies to specific products that complete the PMTA review process. A brand name alone does not receive authorization, and each product must be reviewed individually.
Q4: Are nicotine pouches risk-free?
No. Nicotine pouches are not risk-free products. FDA authorization means the products have undergone regulatory review, not that they are completely safe.
